Middle
East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market,
by Drug Type (Steroid, Immunoglobulins, Thrombopoietin Receptor Agonist and
Others, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and
Online Pharmacies), and By Country (Turkey, Israel, Egypt, Saudi Arabia, UAE,
and Rest of Middle East) was valued at US$
82.23 million in 2019, and is projected to exhibit a CAGR of 4.0% over
the forecast period (2019 - 2027), as highlighted in a new report published by
Coherent Market Insights.
Increasing number of clinical
trials, rising government support and healthcare spending for development of
better medical facilities in the Middle East are the major factors that are
expected to drive growth of the Middle East and Turkey immune Thrombocytopenic
Purpura (ITP) Treatment Drugs Market. Various organizations are focusing on
developing new solutions for treatment of immune thrombocytopenic purpura which
is expected to favor growth of the Middle East and Turkey immune
Thrombocytopenic Purpura (ITP) Treatment Drugs Market. For instance, in
November 2018, Novartis Pharmaceuticals started a clinical trial to study the
ability of Eltrombopag to induce sustained treatment-free remission in ITP
subjects who relapsed or failed to respond to initial steroids treatment. It is
an interventional clinical trial with more than 100 participants. The clinical
trial is in phase 2 and is expected to complete in May 2022.
Furthermore, launch of new
healthcare plans and programs is expected to fuel growth of the Middle East and
Turkey immune thrombocytopenic purpura drugs market. For instance, in 2010, UAE
Vision 2021 was launched by the Prime Minister of the U.A.E. As part of the
Vision 2021 plan, UAE is aiming to provide 'world class healthcare' in the UAE
by pushing for greater preventive measures to counter lifestyle-related
diseases and rare diseases by implementing an accelerated drug registration
system, and including health as a key sector within the country's wider
innovation strategy.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3171
Increasing healthcare expenditure
in the UAE is expected to boost the market growth over the forecast period. For
instance, according to the Export Gov., 2019 report, UAE’s healthcare
expenditure was US$ 13.7 billion in 2018, and it is expected to reach US$ 18.3
billion by 2023. Furthermore, in 2015, the UAE government launched a new health
insurance scheme in Dubai. Under this scheme 130,000 people get healthcare at
23 private hospitals, and more than 500 medical clinics in and around Dubai.
Browse 20 Market Data Tables and
21 Figures spread through 114 Pages and in-depth TOC on "Middle East and
Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market, By Drug Type
(Steroid, Immunoglobulins, Thrombopoietin Receptor Agonist and Others, By
Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online
Pharmacies), and By Country (Turkey, Israel, Egypt, Saudi Arabia, UAE, and Rest
of Middle East) - Global Forecast to 2027."
Moreover, many pharmaceutical
companies are focusing on entering the Middle East region, which is a highly
untapped region. For instance, in March 2018, Felix Pharmaceuticals Industries
announced the construction of a pharmaceutical plant and logistics center at
the Salalah Free Zone in Oman. The company invested US$ 365 million for
construction of the plant. The project is implemented in three stages, starting
in 2018 and ending in 2021.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/middle-east-and-turkey-immune-thrombocytopenic-purpura-treatment-drugs-market-3171
Key Takeaways of the Middle East
and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market:
The Middle East and Turkey immune
Thrombocytopenic Purpura (ITP) Treatment Drugs Market is expected to expand at
a CAGR of 4.0% during the forecast period (2019–2027) owing to increasing
government support, clinical trials, and healthcare expenditure.
Among drug type, the steroid
segment is expected to hold major revenue share in 2027. Various organizations
are focusing on R&D activities to develop immune thrombocytopenic purpura
drugs. Ongoing research has analyzed the efficacy and safety of high-dose
dexamethasone and prednisone for treatment of patients who have been newly
diagnosed with ITP. The corticosteroid drug has not received approval in any of
the Middle East countries for treating ITP.
Major players operating in the
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs
Market include Amgen Inc., Octapharma AG, Novartis AG, Swedish Orphan Biovitrum
AB, and Rigel Pharmaceuticals, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3171
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment